Pluristem Therapeutics, Inc. (PSTI) financial statements (2021 and earlier)
Company profile
| Business Address |
MATAM ADVANCED TECHNOLOGY PARK HAIFA, 3508409 |
| State of Incorp. | NV |
| Fiscal Year End | June 30 |
| SIC | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2020 TTM | 6/30/2020 | 6/30/2019 | 6/30/2018 | 6/30/2017 | 6/30/2016 | 6/30/2015 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 46 | 59 | 25 | 30 | 26 | 15 | 30 | ||
| Cash and cash equivalents | 8 | 8 | 4 | 9 | 5 | 6 | 23 | ||
| Short-term investments | 35 | 38 | 20 | 21 | 6 | 9 | 7 | ||
| Other undisclosed cash, cash equivalents, and short-term investments | 3 | 13 | 1 | 15 | |||||
| Restricted cash and investments | 0 | 1 | 1 | 1 | 1 | 1 | |||
| Receivables | 0 | 0 | 0 | 1 | 2 | 2 | |||
| Prepaid expense | 1 | ||||||||
| Other current assets | 2 | 2 | 2 | 1 | 1 | 1 | 2 | ||
| Other undisclosed current assets | (3) | (13) | (1) | 17 | 21 | ||||
| Total current assets: | 45 | 48 | 26 | 32 | 29 | 36 | 57 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 1 | 1 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Property, plant and equipment | 2 | 3 | 4 | 6 | 7 | 9 | 10 | ||
| Long-term investments and receivables | 3 | 13 | 0 | 0 | 0 | 0 | 0 | ||
| Long-term investments | 3 | 13 | 0 | 0 | 0 | 0 | 0 | ||
| Other noncurrent assets | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Defined benefit plan, assets for plan benefits | ✕ | ✕ | ✕ | ✕ | 1 | 1 | |||
| Other undisclosed noncurrent assets | 1 | 1 | 1 | 1 | 1 | ||||
| Total noncurrent assets: | 7 | 17 | 5 | 7 | 9 | 10 | 11 | ||
| TOTAL ASSETS: | 52 | 66 | 31 | 39 | 38 | 46 | 68 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 7 | 5 | 7 | 6 | 4 | 4 | 5 | ||
| Accounts payable | 3 | 2 | 2 | 3 | 2 | 3 | 3 | ||
| Accrued liabilities | 4 | 3 | 4 | 2 | 1 | 1 | 1 | ||
| Employee-related liabilities | 0 | 0 | 1 | 1 | 0 | 0 | |||
| Deferred revenue | 0 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Derivative instruments and hedges, liabilities | 0 | ||||||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | 0 | |||||
| Customer advances and deposits | ✕ | ✕ | ✕ | 0 | |||||
| Other undisclosed current liabilities | 3 | 2 | 2 | 2 | 1 | 1 | 1 | ||
| Total current liabilities: | 10 | 8 | 8 | 9 | 5 | 6 | 6 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 0 | 1 | |||||||
| Operating lease, liability | 0 | 1 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Liabilities, other than long-term debt | 1 | 1 | 1 | 2 | 2 | 2 | 4 | ||
| Deferred revenue and credits | ✕ | ✕ | ✕ | 2 | |||||
| Liability, pension and other postretirement and postemployment benefits | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||
| Other liabilities | 0 | 1 | 1 | 1 | 1 | ||||
| Total noncurrent liabilities: | 1 | 1 | 1 | 2 | 2 | 2 | 4 | ||
| Total liabilities: | 11 | 9 | 9 | 10 | 7 | 8 | 10 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | 41 | 56 | 22 | 29 | 30 | 38 | 58 | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | ||||
| Additional paid in capital | 342 | 336 | 273 | 244 | 218 | 198 | 195 | ||
| Accumulated other comprehensive income | 2 | 1 | 2 | ||||||
| Accumulated deficit | (301) | (280) | (251) | (216) | (190) | (162) | (139) | ||
| Receivable from shareholders or affiliates for issuance of capital stock | (1) | ||||||||
| Stockholders' equity note, subscriptions receivable | (41) | (56) | (22) | ✕ | ✕ | ||||
| Other undisclosed stockholders' equity attributable to parent | 41 | 56 | 22 | ||||||
| Total stockholders' equity: | 41 | 56 | 22 | 29 | 30 | 38 | 58 | ||
| TOTAL LIABILITIES AND EQUITY: | 52 | 66 | 31 | 39 | 38 | 46 | 68 | ||
Income statement (P&L) ($ in millions)
| 12/31/2020 TTM | 6/30/2020 | 6/30/2019 | 6/30/2018 | 6/30/2017 | 6/30/2016 | 6/30/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 0 | 0 | 0 | 0 | 0 | 3 | 0 | |
| Revenue, net | ✕ | ✕ | ✕ | 10 | ||||
| Sublease income | 0 | 0 | ✕ | ✕ | ✕ | ✕ | ✕ | |
| Net investment income | 0 | 0 | 0 | 0 | 0 | |||
| Other income | 0 | ✕ | ||||||
| Cost of revenue | (0) | (0) | (0) | (0) | ||||
| Other undisclosed gross profit | 0 | |||||||
| Gross profit: | 0 | 0 | 0 | 0 | 0 | 3 | 0 | |
| Operating expenses | (38) | (31) | (39) | (38) | (31) | (29) | (30) | |
| Other undisclosed operating income | 0 | 2 | 3 | 4 | 3 | 3 | 4 | |
| Operating loss: | (38) | (29) | (36) | (34) | (28) | (23) | (25) | |
| Nonoperating income | 0 | 0 | 0 | 8 | 0 | 0 | 1 | |
| Investment income, nonoperating | (0) | (0) | 0 | (0) | 0 | |||
| Foreign currency transaction gain (loss), before tax | (0) | (0) | 0 | 0 | (0) | (1) | ||
| Other nonoperating income (expense) | (0) | (0) | 0 | |||||
| Net loss: | (37) | (29) | (35) | (26) | (28) | (23) | (25) | |
| Other undisclosed net income attributable to parent | 1 | |||||||
| Net loss available to common stockholders, diluted: | (37) | (29) | (35) | (26) | (28) | (23) | (25) | |
Comprehensive Income ($ in millions)
| 12/31/2020 TTM | 6/30/2020 | 6/30/2019 | 6/30/2018 | 6/30/2017 | 6/30/2016 | 6/30/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (37) | (29) | (35) | (26) | (28) | (23) | (25) | |
| Other comprehensive income (loss) | (2) | 1 | (1) | (1) | ||||
| Comprehensive loss, net of tax, attributable to parent: | (37) | (29) | (35) | (28) | (27) | (24) | (25) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.